A Critical Review on Lipid Nanoparticle-based siRNA Formulations for Breast Cancer Management

Breast cancer poses a formidable challenge due to its inherent difficulty in treatment. Recognizing the imperative need for new therapeutic approaches, this study focuses on a groundbreaking technique that has the potential to reshape breast cancer treatment: siRNA formulations based on lipid nanoparticles (LNPs). This novel method holds promise for transforming the landscape of breast cancer therapy. The primary objective of this research is to conduct a comprehensive assessment of the current state of the art in the field, specifically exploring the potential applications of siRNA treatments encapsulated in LNPs for breast cancer. The research methodology involves a detailed literature review covering breast cancer, siRNA therapy, and lipid nanoparticles. The study investigates the fundamental principles of siRNA therapy, highlighting its capacity to selectively silence genes critical to breast cancer development. Additionally, the application of LNPs in delivering therapeutic siRNA payloads is explored, with an emphasis on the benefits of LNPs, including their biocompatibility and effective siRNA incorporation. Safety and effectiveness characteristics of LNP-based siRNA formulations are also assessed to pave the way for potential therapeutic applications. Findings from the study illuminate the promising characteristics of LNP-siRNA formulations in the treatment of breast cancer. The investigation provides insights into targeting strategies, such as the enhanced permeability and retention (EPR) effect and the utilization of ligand-conjugated nanoparticles. The study outlines potential avenues for therapeutic use, drawing attention to the safety and effectiveness of LNP-based siRNA formulations. In summary, this study aims to reveal intricate interactions between lipid nanoparticle-based siRNA formulations and breast cancer treatment, fostering a transformation in the field by highlighting current developments, future trends, and innovative strategies for next-gen LNP-based siRNA formulations.